Cargando…

Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity

PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Thomas, O’Cathail, Sean M., Silverman, Sabrina, Robinson, Maxwell, Tsang, Yatman, Harrison, Mark, Hawkins, Maria A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718547/
https://www.ncbi.nlm.nih.gov/pubmed/33305093
http://dx.doi.org/10.1016/j.adro.2020.07.017
_version_ 1783619513481166848
author Smith, Thomas
O’Cathail, Sean M.
Silverman, Sabrina
Robinson, Maxwell
Tsang, Yatman
Harrison, Mark
Hawkins, Maria A.
author_facet Smith, Thomas
O’Cathail, Sean M.
Silverman, Sabrina
Robinson, Maxwell
Tsang, Yatman
Harrison, Mark
Hawkins, Maria A.
author_sort Smith, Thomas
collection PubMed
description PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm(3). In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity.
format Online
Article
Text
id pubmed-7718547
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-77185472020-12-09 Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity Smith, Thomas O’Cathail, Sean M. Silverman, Sabrina Robinson, Maxwell Tsang, Yatman Harrison, Mark Hawkins, Maria A. Adv Radiat Oncol Scientific Article PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm(3). In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity. Elsevier 2020-08-07 /pmc/articles/PMC7718547/ /pubmed/33305093 http://dx.doi.org/10.1016/j.adro.2020.07.017 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Scientific Article
Smith, Thomas
O’Cathail, Sean M.
Silverman, Sabrina
Robinson, Maxwell
Tsang, Yatman
Harrison, Mark
Hawkins, Maria A.
Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title_full Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title_fullStr Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title_full_unstemmed Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title_short Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity
title_sort stereotactic body radiation therapy reirradiation for locally recurrent rectal cancer: outcomes and toxicity
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718547/
https://www.ncbi.nlm.nih.gov/pubmed/33305093
http://dx.doi.org/10.1016/j.adro.2020.07.017
work_keys_str_mv AT smiththomas stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT ocathailseanm stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT silvermansabrina stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT robinsonmaxwell stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT tsangyatman stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT harrisonmark stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity
AT hawkinsmariaa stereotacticbodyradiationtherapyreirradiationforlocallyrecurrentrectalcanceroutcomesandtoxicity